Case law: A review of selected pharmaceutical patents litigated in the UK courts during 2022

Patents lie at the interface between technology and law. This review provides a summary of four high profile cases from 2022 in which patents in the pharmaceutical or medical space were litigated in the UK Courts. The first case concerns Astellas' patent for Betmiga (mirabegron) for overactive...

Full description

Saved in:
Bibliographic Details
Published in:British Journal of Pharmacy Vol. 8; no. 1; pp. 1 - 8
Main Authors: Crawford, Sarah-Jane, O'Brien, Harry Melville, Stones, James Alexander
Format: Journal Article
Language:English
Published: Huddersfield, United Kingdom University of Huddersfield Press 31.12.2023
Subjects:
Bladder
Diseases
Patent infringement
Patent laws and legislation
Pharmaceutical industry
Technological innovations
Treatment
ISSN:2058-8356, 2058-8356
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patents lie at the interface between technology and law. This review provides a summary of four high profile cases from 2022 in which patents in the pharmaceutical or medical space were litigated in the UK Courts. The first case concerns Astellas' patent for Betmiga (mirabegron) for overactive bladder. The second case involves a patent to Bristol-Meyers Squibb for Eliquis (apixaban) for thromboembolic disorders. The third case concerns Novartis' patent for Exjade (deferasirox) for use in the treatment of conditions involving excess iron in the blood caused by haemochromatosis, etc. In the final case, Novartis defended its patent for Gilenya (fingolimod) as a disease modifying therapy for relapsing remitting multiple sclerosis. The article aims to focus on the technology behind the patents and to provide an insight into how science interacts with law in the context of patent enforcement and infringement.
Bibliography:Informit, Melbourne (Vic)
British Journal of Pharmacy, Vol. 8, No. 1, Apr 2023, 1-8
ISSN:2058-8356
2058-8356
DOI:10.5920/bjpharm.1346